Can (Alan) C.’s Post

Our partner,Can (Alan) C. is publishing a series of posts on social media to introduce Chinese deep tech startups to the Australian deep tech ecosystem. The purpose is to assist Australian deep tech investors and founders in gaining a better understanding of the innovation landscape and providing more effective support to Australian deep tech startups in their global expansion endeavors.

Sadly, cancer touches more and more people globally. 🏥 TILT Biotherapeutics Ltd, a Finnish biotech company, develops cancer immunotherapies with armed oncolytic viruses to destroy cancer cells. Since its establishment in 2013, TILT Biotherapeutics has raised more than EUR 60 million in financing, of which about EUR 45 million in venture capital. Health and life sciences is one of Tesi's strategic investment themes. That in mind, Tesi has participated in two of TILT's financing rounds – 2022 and 2024. Read more about the TILT and Tesi's role on its growth path in our case article! 👇 https://lnkd.in/dB4Q7-88 #VentureCapital #HealthandLifeSciences #BioTechnology

We are excited to share that RECEPTOR.AI is entering in partnership with Moexa Pharmaceuticals, Inc. to drive the discovery and development of novel small molecule therapeutics targeting protein-protein interactions (PPIs) for cancer and fibrosis treatment. This collaboration will leverage our Induced Proximity Platform, to develop PPIs modulating compounds, advancing the frontiers of AI-powered drug discovery. Together with Moexa's deep expertise in cancer and fibrosis biology, we are poised to accelerate the creation of transformative therapies. For more details, visit our website and read the full press release: https://lnkd.in/ejG7xSt7 Learn more about our Induced Proximity Platform: https://lnkd.in/eNfRMx_P #Partnership #AI #DrugDiscovery #Cancer #Fibrosis #Biotechnology #Innovation

Today, we announced preclinical data for potential first-in-class medicines, including FHD-909, a BRM (SMARCA2) selective inhibitor, and our selective CBP degrader and selective EP300 degrader programs at the 2024 American Association for Cancer Research Annual Meeting. Learn about the data, and don't forget to register for the webcast at 5 pm ET: https://bit.ly/4aOkbZz #biotechnology #innovation #oncology #drugdevelopment #AACR24

ATTN #BIO2024: Today at 2:30 pm, our CEO, Bob Linke, gives a company presentation about OSM-0205, our lead product. We look forward to providing an update on our plans for OSM-0205, which is poised to initiate clinical development later this year. OSM-0205 is a preventative treatment to help patients avoid the painful and debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN), common amongst taxane-based chemotherapies, including the leading breast cancer chemotherapy treatment. CIPN affects as many as 80% of these cancer patients and can significantly impact both quality of life and survival. Stop by to see our company presentation or request a meeting with our CEO, Bob Linke through, the Biotechnology Innovation Organization (BIO) One-on-One Partnering™ System: https://lnkd.in/eEDtKaAK #oncology #biotech #investors

🌟𝗡𝗲𝘄 𝗕𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗶𝗻 𝗦𝘁𝗼𝗰𝗸: 𝗧𝗲𝗰𝗹𝗶𝘀𝘁𝗮𝗺𝗮𝗯🚀🧬 Teclistamab from the original drug Tecvayli®, a new #bispecific antibody, is making strides in the fight against multiple myeloma. 💪 Utilizing advanced biotechnology, Teclistamab simultaneously targets T cells and cancer cells, recruiting T cells to destroy the malignant cells. This innovative approach offers new hope for patients battling this incurable blood cancer. 🎗️ Visit our online shop to access Teclistamab and other licensed molecules in smaller units. 🛒 We also offer historical batches of original and biosimilar drugs for your research and early drug development projects. 🔬 #antibody #bloodcancer #biotechnology #cancerresearch #immunotherapy #globalreach #research #drugdevelopment #accessibleresearch

This week, our CSO, Nick Stub Laursen, will be attending the 16th International Conference on Complement Therapeutics in Loutraki, Ancient Corinth, Greece.    Nick will be delivering a poster presentation on new data from Commit Biologics innovative BiCE platform which will show that Commit’s second generation #BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies.   With a novel mechanism of action, Commit’s technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases.   To read more on the presentation, read the press release in the comments below!   #ComplementSystem #ImmuneSystem #Antibodies

💡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲! Ipsen and BIOMUNEX PHARMACEUTICALS are teaming up in the fight against cancer with an exclusive global licensing agreement for BMX-502—a first-in-class MAIT cell engager. 🚀 BMX-502 targets GPC3, a clinically validated tumor antigen, while harnessing the power of 𝐌𝐮𝐜𝐨𝐬𝐚𝐥-𝐀𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐈𝐧𝐯𝐚𝐫𝐢𝐚𝐧𝐭 𝐓 (𝐌𝐀𝐈𝐓) 𝐜𝐞𝐥𝐥𝐬. This groundbreaking bispecific antibody leverages MAIT cells' unique properties to overcome the challenges of traditional T-cell therapies, such as dose-limiting toxicities and cytokine release syndrome. This partnership underscores Ipsen’s commitment to building a robust oncology pipeline and Biomunex’s expertise in disruptive immunotherapies. Together, we’re moving closer to transforming #cancertreatment! 🔗 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐞𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭:  https://lnkd.in/gyGqtK8V #immunooncology #cancerresearch #biotechinnovation #ipsen #biomunex #maitcells #oncologypartnerships #tcellengagers #biotechnology

#ACROHighlights [Featured Product] 🔑 Unleash the Potential of MMPs in Cancer Therapeutics 🔬 Unlock the secrets of the tumor microenvironment with our recombinant MMP proteins. Matrix Metalloproteinases (MMPs) are key players in remodeling the TME, driving tumor growth, invasion, and metastasis. Explore our premium MMP products (MMP-1, MMP-2, MMP-3, and more) to uncover new cancer research and therapeutic development frontiers. Leverage the versatile capabilities of these enzymes to propel your pharmaceutical R&D to new heights. 💊💪 🔗https://lnkd.in/gm7TPZbd #TumorMicroenvironment #MatrixMetalloproteinases #CancerResearch #Biotechnology #MMPs

With flu season upon us, imagine if it someday became a thing of the past. Eradivir, a preclinical biotech company dedicated to developing antiviral therapeutics, is working to make that vision a reality. The company has raised over $10 million in a Series A funding round, which will be used to conduct studies on its influenza treatment. Read more about it and the many other impacts #Boilermakers have made throughout the year: https://lnkd.in/gzeB2sAE Martin Low | Philip Low | Purdue University College of Science | Purdue Institute for Drug Discovery | Purdue Institute for Cancer Research #Purdue #PurdueInnovates #Influenza #Therapeutics